- Home
- GSK vs BDX Comparison
GSK vs BDX Comparison
Compare GSK & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | BDX |
|---|---|---|
| Founded | 1715 | 1897 |
| Country | United Kingdom | United States |
| Employees | N/A | 72000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0B | 49.4B |
| IPO Year | 2013 | 1998 |
Fundamental Metrics
Financial Performance| Metric | GSK | BDX |
|---|---|---|
| Price | $49.81 | $182.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | N/A | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.40% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $4.19 | $3.02 |
| P/E Ratio | ★ $32.75 | $115.09 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $39.29 | $140.11 |
| 52 Week High | $61.70 | $213.08 |
Technical Indicators
Market Signals| Indicator | GSK | BDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About BDX Becton Dickinson and Company
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.